Share Email Print
cover

Proceedings Paper

Evaluation of photodynamic antimicrobial therapy (PACT) against promastigotes form of the Leishmania (Viannia) braziliensis: in vitro study
Author(s): Artur F. S. Barbosa; Bruno B. Sangiorgi; Suely L. Galdino; Ivan R. Pitta; Manoel Barral Netto; Neandder A. Correia; Antônio L. B. Pinheiro
Format Member Price Non-Member Price
PDF $14.40 $18.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

Leishmaniasis is a complex disease that affects more than 12 million people in 88 countries worldwide. Leishmania (Viannia) braziliensis is the most common species in the Americas and the most important causative agent of cutaneous and mucocutaneous leishmaniasis in Brazil. The therapeutic arsenal routinely employed to treat patients with leishmaniasis is limited and unsatisfactory. For cutaneous leishmaniasis, pentavalent antimonials are the first line therapeutic scheme recommended by the WHO. These compounds are highly toxic, poorly tolerated and their effectiveness highly variable. In this work, a technique with, so far, an unknown disadvantage is discussed. The aim of this study was to verify the effectiveness of PACT in vitro, as a new technique for the treatment of Leishmaniasis. For this, semiconductor laser (λ = 660nm, 40mW, 4.2J/cm2, CW) associated to phenothiazine's derivatives (5 and 10 μg/ml, TBO, Methylene Blue or Phenothiazine) on the promastigotes form of Leishmania braziliensis in a single session was used. Viability of the parasites was assessed in quadruplicates of each group. The samples were removed and analyzed in a hemocytometer 72h after PACT. We found an important decrease in the number of viable parasites on all treated groups in comparison to their controls. The results of present study showed significant percentage of lethality (above 95%) of the protocol. The 99.23% of lethality was achieved with 10 μg/ml of TBO. No lethality was seen on groups treated neither with laser nor with each compounds separately. The results are promising and indicative that the use of PACT may be a powerful treatment of leishmaniasis when compared to already available ones.

Paper Details

Date Published: 9 March 2012
PDF: 7 pages
Proc. SPIE 8211, Mechanisms for Low-Light Therapy VII, 82110N (9 March 2012); doi: 10.1117/12.909409
Show Author Affiliations
Artur F. S. Barbosa, Univ. Federal de Pernambuco (Brazil)
Research Ctr. Gonçalo Moniz (Brazil)
Univ. Federal da Bahia (Brazil)
Bruno B. Sangiorgi, Research Ctr. Gonçalo Moniz (Brazil)
Suely L. Galdino, Univ. Federal de Pernambuco (Brazil)
Ivan R. Pitta, Univ. Federal de Pernambuco (Brazil)
Manoel Barral Netto, Research Ctr. Gonçalo Moniz (Brazil)
Neandder A. Correia, Univ. Federal da Bahia (Brazil)
Antônio L. B. Pinheiro, Univ. Federal da Bahia (Brazil)
Univ. de São Paulo (Brazil)


Published in SPIE Proceedings Vol. 8211:
Mechanisms for Low-Light Therapy VII
Michael R. Hamblin; Juanita Anders; James D. Carroll, Editor(s)

© SPIE. Terms of Use
Back to Top